Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy ...

COOMBS: We have so many effective therapies that it is often difficult to choose. Bruton tyrosine kinase [BTK] inhibitors are the mainstay in CLL, with ibrutinib [Imbruvica] being the first approved, ...

While much about modern farming techniques centers around the use of synthetic pesticides (a catch-all term that includes herbicides, insecticides, fungicides, and other similar substances) on large ...

前日，制药巨头礼来在官网上官宣将其重磅产品三代BTK抑制剂匹妥布替尼（Pirtobrutinib）中国区商业化权益授权给国内创新药公司信达生物。作为国内 ...

During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome ...